AI Takeaway
PODD delivered a strong Q1 FY2026 with revenue surging 33.9% YoY to $761.7M and net income more than doubling to $91.1M, while the company returned $300M to shareholders via buybacks.
Revenue
$761.7M
++33.87% YoY
EPS (Basic)
$1.30
++160.00% YoY
Gross Margin
69.5%
-2.42% YoY
Operating Income
$122.1M
++37.50% YoY
Filed · Analysis updated · Source: SEC EDGAR 10-Q filing
Revenue grew 33.9% YoY to $761.7M in Q1 FY2026 from $569.0M in Q1 FY2025, reflecting strong demand for PODD's insulin delivery products and continued market penetration.
Source: Source: 10-Q Income Statement
Net income jumped 157.3% YoY to $91.1M from $35.4M, with EPS (diluted) rising to $1.30 from $0.50, indicating significant operating leverage as revenue growth outpaced expense growth.
Source: Source: 10-Q Income Statement
R&D expenses increased 50.5% YoY to $89.7M, outpacing revenue growth, signaling continued heavy investment in product innovation and pipeline development to sustain long-term competitive positioning.
Source: Source: 10-Q Income Statement
2 more insights available
Upgrade to unlockGross margin declined 240 basis points YoY to 69.5% from 71.9%, as cost of revenue grew 45.5%—significantly faster than revenue growth of 33.9%. Sustained cost pressure could erode profitability if not offset by pricing power or operational efficiencies.
Source: Source: 10-Q Income Statement & Key Ratios
Unlock 4 more detailed risk analysis
Upgrade to unlockReported EPS of $1.42 versus the $1.22 analyst consensus — a +16.2% beat for Q1 FY2026.
| Metric | Current | Previous | YoY Change |
|---|---|---|---|
Revenue | $761.7M | $569M | +33.87% |
Cost of Revenue | $232.7M | $159.9M | +45.53% |
Gross Profit | $529.1M | $409M | +29.36% |
Operating Income | $122.1M | $88.8M | +37.50% |
Net Income | $91.1M | $35.4M | +157.34% |
EPS (Basic) | $1.30 | $0.50 | +160.00% |
EPS (Diluted) | $1.30 | $0.50 | +160.00% |
R&D Expense | $89.7M | $59.6M | +50.50% |
SG&A Expense | $317.2M | $260.7M | +21.67% |
| Metric | Current | Previous | YoY Change |
|---|---|---|---|
Total Assets | $2.99B | $3.52B | -15.07% |
Current Assets | $1.71B | $2.33B | -26.58% |
Total Liabilities | $1.68B | $2.19B | -22.96% |
Current Liabilities | $687.5M | $520.4M | +32.11% |
Stockholders' Equity | $1.3B | $1.33B | -2.10% |
| Metric | Current | Previous | YoY Change |
|---|---|---|---|
Operating Cash Flow | $113.8M | $63.8M | +78.37% |
Investing Cash Flow | $-27.7M | $-15.6M | -77.56% |
Financing Cash Flow | $-319.9M | $277.7M | -215.20% |
Share Buybacks | $300M | $0 | — |
D&A | $26.2M | $21.7M | +20.74% |
| Metric | Current | Previous | YoY Change |
|---|---|---|---|
Gross Margin | 69.5% | 71.9% | -2.42% |
Operating Margin | 16.0% | 15.6% | +0.42% |
Net Margin | 12.0% | — | — |
ROE | 7.0% | — | — |
ROA | 3.0% | — | — |
Current Ratio | $2.487 | — | — |
Debt to Equity | $1.293 | — | — |
Other companies in Health Care Equipment
PODD's revenue grew 33.9% YoY to $761.7M in Q1 FY2026, up from $569.0M in Q1 FY2025. This strong growth reflects continued strong demand for the company's insulin delivery products and expanding market penetration.
The headline takeaways from PODD's Q1 FY2026 report are a 33.9% revenue surge to $761.7M, a 157.3% jump in net income to $91.1M, and a $300M share buyback. Operating cash flow also nearly doubled to $113.8M, signaling strong underlying business momentum.
PODD's gross margin declined approximately 240 basis points YoY to 69.5% as cost of revenue grew faster (45.5%) than revenue (33.9%). However, operating margin improved slightly to 16.0% from 15.6%, showing the company is still gaining operating leverage overall.
Based on the financial data, key risks include gross margin compression from rising production costs, a 32.1% increase in current liabilities, and a debt-to-equity ratio of 1.29 indicating meaningful leverage. The $300M share buyback also reduced the company's cash cushion, lowering total assets by 15.1% YoY.
PODD's financial health appears solid with a current ratio of 2.49, operating cash flow of $113.8M, and net income of $91.1M. However, total assets declined 15.1% YoY to $3.0B largely due to the $300M buyback, and the debt-to-equity ratio of 1.29 warrants ongoing monitoring.